224 related articles for article (PubMed ID: 15718306)
1. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Goetz MP; Toft D; Reid J; Ames M; Stensgard B; Safgren S; Adjei AA; Sloan J; Atherton P; Vasile V; Salazaar S; Adjei A; Croghan G; Erlichman C
J Clin Oncol; 2005 Feb; 23(6):1078-87. PubMed ID: 15718306
[TBL] [Abstract][Full Text] [Related]
2. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
[TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
Bagatell R; Gore L; Egorin MJ; Ho R; Heller G; Boucher N; Zuhowski EG; Whitlock JA; Hunger SP; Narendran A; Katzenstein HM; Arceci RJ; Boklan J; Herzog CE; Whitesell L; Ivy SP; Trippett TM
Clin Cancer Res; 2007 Mar; 13(6):1783-8. PubMed ID: 17363533
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer.
Nowakowski GS; McCollum AK; Ames MM; Mandrekar SJ; Reid JM; Adjei AA; Toft DO; Safgren SL; Erlichman C
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6087-93. PubMed ID: 17062684
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.
Grem JL; Morrison G; Guo XD; Agnew E; Takimoto CH; Thomas R; Szabo E; Grochow L; Grollman F; Hamilton JM; Neckers L; Wilson RH
J Clin Oncol; 2005 Mar; 23(9):1885-93. PubMed ID: 15774780
[TBL] [Abstract][Full Text] [Related]
6. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D
Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374
[TBL] [Abstract][Full Text] [Related]
7. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.
Banerji U; O'Donnell A; Scurr M; Pacey S; Stapleton S; Asad Y; Simmons L; Maloney A; Raynaud F; Campbell M; Walton M; Lakhani S; Kaye S; Workman P; Judson I
J Clin Oncol; 2005 Jun; 23(18):4152-61. PubMed ID: 15961763
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI
Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
Hubbard J; Erlichman C; Toft DO; Qin R; Stensgard BA; Felten S; Ten Eyck C; Batzel G; Ivy SP; Haluska P
Invest New Drugs; 2011 Jun; 29(3):473-80. PubMed ID: 20082116
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
Ramanathan RK; Egorin MJ; Eiseman JL; Ramalingam S; Friedland D; Agarwala SS; Ivy SP; Potter DM; Chatta G; Zuhowski EG; Stoller RG; Naret C; Guo J; Belani CP
Clin Cancer Res; 2007 Mar; 13(6):1769-74. PubMed ID: 17363531
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
Kummar S; Gutierrez ME; Gardner ER; Chen X; Figg WD; Zajac-Kaye M; Chen M; Steinberg SM; Muir CA; Yancey MA; Horneffer YR; Juwara L; Melillo G; Ivy SP; Merino M; Neckers L; Steeg PS; Conley BA; Giaccone G; Doroshow JH; Murgo AJ
Eur J Cancer; 2010 Jan; 46(2):340-7. PubMed ID: 19945858
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Iyer G; Morris MJ; Rathkopf D; Slovin SF; Steers M; Larson SM; Schwartz LH; Curley T; DeLaCruz A; Ye Q; Heller G; Egorin MJ; Ivy SP; Rosen N; Scher HI; Solit DB
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1089-97. PubMed ID: 22124669
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.
Lancet JE; Gojo I; Burton M; Quinn M; Tighe SM; Kersey K; Zhong Z; Albitar MX; Bhalla K; Hannah AL; Baer MR
Leukemia; 2010 Apr; 24(4):699-705. PubMed ID: 20111068
[TBL] [Abstract][Full Text] [Related]
16. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
17. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
[TBL] [Abstract][Full Text] [Related]
18. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.
Jhaveri K; Miller K; Rosen L; Schneider B; Chap L; Hannah A; Zhong Z; Ma W; Hudis C; Modi S
Clin Cancer Res; 2012 Sep; 18(18):5090-8. PubMed ID: 22781552
[TBL] [Abstract][Full Text] [Related]
19. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
